PE20130152A1 - Derivados de heterociclo biciclicos como inhibidores de proteina quinasa b - Google Patents
Derivados de heterociclo biciclicos como inhibidores de proteina quinasa bInfo
- Publication number
- PE20130152A1 PE20130152A1 PE2012002041A PE2012002041A PE20130152A1 PE 20130152 A1 PE20130152 A1 PE 20130152A1 PE 2012002041 A PE2012002041 A PE 2012002041A PE 2012002041 A PE2012002041 A PE 2012002041A PE 20130152 A1 PE20130152 A1 PE 20130152A1
- Authority
- PE
- Peru
- Prior art keywords
- protein kinase
- cyane
- bromine
- chlorine
- fluorine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE: Y ES CH O N; Z1-Z2 ES C(R6)=CH, N=CH Y C(R6)=N; R6 ES H, FLUORO, CLORO, BROMO, CIANO, METILO, ENTRE OTROS; R1 ES ALQUILO C1-4, ALCOXI C1-4, METOXIALQUILO C1-4, AMINOALQUILO C1-4, FLUOROALQUILO C1-4, CIANO, CIANOALQUILO C1-4; R4 ES H, FLUORO, CLORO, BROMO, CIANO O TRIFLUOROMETILO; R5 ES H, FLUORO, CLORO O BROMO. SON COMPUESTOS PREFERIDOS: 4-AMINO-N-(1-(4-CLOROFENIL)ETIL)-1-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)PIPERIDINA-4-CARBOXAMIDA; 4-AMINO-N-(1-(4-CLOROFENIL)PROPIL)-1-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)PIPERIDINA-4-CARBOXAMIDA; ENTRE OTROS. REFERIDO ADEMAS A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO O AFECCIONES MEDICAS MEDIADAS POR LA ACTIVIDAD DE LA PROTEINA QUINASA B (PKB) TAL COMO CANCER DE OVARIOS, LEUCEMIA, LINFOMA, CANCER CERVICAL
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97919207P | 2007-10-11 | 2007-10-11 | |
US4786208P | 2008-04-25 | 2008-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130152A1 true PE20130152A1 (es) | 2013-03-17 |
Family
ID=40251789
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012002041A PE20130152A1 (es) | 2007-10-11 | 2008-10-10 | Derivados de heterociclo biciclicos como inhibidores de proteina quinasa b |
PE2008001748A PE20090964A1 (es) | 2007-10-11 | 2008-10-10 | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001748A PE20090964A1 (es) | 2007-10-11 | 2008-10-10 | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b |
Country Status (38)
Country | Link |
---|---|
US (8) | US8101623B2 (es) |
EP (1) | EP2201012B1 (es) |
JP (2) | JP4705695B2 (es) |
KR (1) | KR101494734B1 (es) |
CN (1) | CN101861321B (es) |
AR (1) | AR068846A1 (es) |
AU (1) | AU2008309383B2 (es) |
BR (1) | BRPI0818533B8 (es) |
CA (1) | CA2701057C (es) |
CL (1) | CL2008003023A1 (es) |
CO (1) | CO6270328A2 (es) |
CR (1) | CR11359A (es) |
CU (1) | CU23886B1 (es) |
CY (1) | CY1116929T1 (es) |
DK (1) | DK2201012T3 (es) |
DO (1) | DOP2010000103A (es) |
EA (1) | EA018512B1 (es) |
ES (1) | ES2522365T3 (es) |
GT (1) | GT201000082A (es) |
HK (1) | HK1143154A1 (es) |
HN (1) | HN2010000653A (es) |
HR (1) | HRP20140807T1 (es) |
IL (1) | IL204721A (es) |
ME (1) | ME01999B (es) |
MX (1) | MX2010003927A (es) |
MY (1) | MY150059A (es) |
NI (1) | NI201000050A (es) |
NZ (1) | NZ585261A (es) |
PE (2) | PE20130152A1 (es) |
PL (1) | PL2201012T3 (es) |
PT (1) | PT2201012E (es) |
RS (1) | RS53552B1 (es) |
SA (1) | SA08290625B1 (es) |
SI (1) | SI2201012T1 (es) |
TW (1) | TWI453021B (es) |
UY (1) | UY31384A1 (es) |
WO (1) | WO2009047563A1 (es) |
ZA (1) | ZA201002318B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
KR20090064378A (ko) | 2006-08-10 | 2009-06-18 | 온코세라피 사이언스 가부시키가이샤 | 유방암 관련 유전자 및 폴리펩티드 |
SI2201012T1 (sl) | 2007-10-11 | 2014-10-30 | Astrazeneca Ab | Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B |
WO2011002772A1 (en) * | 2009-06-29 | 2011-01-06 | Oncotherapy Science, Inc. | Imidazopyridine derivatives and pbk inhibitors containing the same |
GB201020161D0 (en) | 2010-11-26 | 2011-01-12 | Almac Discovery Ltd | Pharmaceutical compounds |
WO2012080735A1 (en) | 2010-12-16 | 2012-06-21 | Convergence Pharmaceuticals Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
KR20140053836A (ko) | 2011-01-11 | 2014-05-08 | 글락소스미스클라인 엘엘씨 | 조합물 |
DK2694056T3 (da) * | 2011-04-01 | 2020-01-02 | Astrazeneca Ab | Terapeutisk behandling |
AU2013205648B2 (en) * | 2011-11-30 | 2015-02-05 | Astrazeneca Ab | Combination treatment |
MY175800A (en) * | 2011-11-30 | 2020-07-09 | Astrazeneca Ab | Combination treatment of cancer |
AU2013204533B2 (en) * | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
AU2014208964B2 (en) | 2013-01-23 | 2016-09-01 | Astrazeneca Ab | Chemical compounds |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
KR20160104612A (ko) | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조성물 |
JP6295578B2 (ja) * | 2013-09-30 | 2018-03-20 | 凸版印刷株式会社 | 反応容器、核酸解析装置、および核酸解析方法 |
EP3718544A1 (en) * | 2013-10-01 | 2020-10-07 | Novartis AG | Combination |
SG11201606689VA (en) | 2014-02-13 | 2016-09-29 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
BR112016018555B1 (pt) | 2014-02-13 | 2024-01-23 | Incyte Holdings Corporation | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 |
ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
ES2691223T3 (es) * | 2014-05-28 | 2018-11-26 | Astrazeneca Ab | Proceso para la preparación de AZD5363 e intermedio novedoso utilizado en el mismo |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
US9944647B2 (en) | 2015-04-03 | 2018-04-17 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US10329255B2 (en) * | 2015-08-12 | 2019-06-25 | Incyte Corporation | Salts of an LSD1 inhibitor |
TW201726140A (zh) | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
AU2017252328B2 (en) | 2016-04-22 | 2023-02-23 | Incyte Corporation | Formulations of an LSD1 inhibitor |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
EP4054582A1 (en) | 2019-11-04 | 2022-09-14 | Astrazeneca AB | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
WO2022147519A1 (en) * | 2021-01-04 | 2022-07-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of capivasertib and process for preparation thereof |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
CN114601836B (zh) * | 2022-04-12 | 2022-12-06 | 四川大学华西医院 | 一种akt抑制剂在制备治疗乳腺癌的药物中的应用 |
WO2024083716A1 (en) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
WO2024104561A1 (en) | 2022-11-15 | 2024-05-23 | Astrazeneca Ab | Therapeutic combinations of capivasertib and venetoclax |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL297170A (es) | 1963-04-04 | 1900-01-01 | ||
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
JP2001519766A (ja) | 1996-04-03 | 2001-10-23 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼの阻害剤 |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
JP4367866B2 (ja) | 1997-02-12 | 2009-11-18 | ザ リージェンツ オブ ジ ユニバーシティ オブ ミシガン | 肺癌用のタンパク質マーカーおよびその使用 |
US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
TR200000333T2 (tr) | 1997-08-05 | 2000-05-22 | Pfizer Products Inc. | Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler. |
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
CA2333770A1 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
ES2306306T3 (es) | 1999-11-05 | 2008-11-01 | Astrazeneca Ab | Nuevos derivados de quinazolina. |
US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
CZ303705B6 (cs) | 2000-02-15 | 2013-03-27 | Sugen, Inc. | Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem |
MXPA02011770A (es) | 2000-05-31 | 2003-04-10 | Astrazeneca Ab | Derivados de indol con actividad de dano vascular. |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
SI1294724T1 (sl) | 2000-06-26 | 2006-08-31 | Pfizer Prod Inc | Pirolo(2,3-d)primidinske spojine kot imunosupresivna sredstva |
WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
CN1308324C (zh) | 2000-08-31 | 2007-04-04 | 弗·哈夫曼-拉罗切有限公司 | 作为α-1肾上腺素能拮抗剂的喹唑啉衍生物 |
HUP0400692A3 (en) | 2000-12-01 | 2007-09-28 | Osi Pharmaceuticals | Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them |
US6680324B2 (en) * | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6673802B2 (en) * | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
MXPA03009846A (es) * | 2001-04-27 | 2004-05-05 | Vertex Pharma | Derivados de triazol inhibidores de cinasa y usos de los mismos. |
CN100503608C (zh) | 2002-01-07 | 2009-06-24 | 卫材R&D管理株式会社 | 脱氮嘌呤及其用途 |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
TW200410688A (en) * | 2002-06-26 | 2004-07-01 | Ono Pharmaceutical Co | Therapeutics for diseases from vasoconstriction or vasodilatation |
US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
EP1551410A2 (en) | 2002-09-06 | 2005-07-13 | Smithkline Beecham Corporation | Novel compounds |
EP1567495A4 (en) | 2002-11-08 | 2007-10-31 | Harvard College | SMALL, WITH TECHNETIUM-99M AND RHENIUM-MARKED MEDIUM AND METHOD OF ILLUMINATING WOVEN FABRICS, ORGANS AND TUMORS |
RU2328498C9 (ru) * | 2002-12-04 | 2008-12-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соединения с конденсированным 1,3-дигидроимидазольным циклом |
EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
MXPA05009722A (es) | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
CN1720246A (zh) | 2003-04-21 | 2006-01-11 | 捷克共和国乌斯塔夫化学与生物化学研究院 | (嘌呤-6-基)氨基酸及其制备方法 |
FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス, インコーポレイテッド | c−Kit調節因子および使用方法 |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
CN1882347A (zh) | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
US7511159B2 (en) * | 2003-12-25 | 2009-03-31 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
WO2005095386A1 (en) * | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
CA2563699C (en) * | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
US7994172B2 (en) * | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
WO2006091450A1 (en) | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
EP1910358A2 (en) | 2005-07-14 | 2008-04-16 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
CA2635899A1 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
WO2007125315A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP2009536620A (ja) | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
EP2013206A1 (en) | 2006-04-25 | 2009-01-14 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2007125325A1 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
MX2009006700A (es) | 2006-12-21 | 2009-06-30 | Vertex Pharma | Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas. |
AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
SI2201012T1 (sl) | 2007-10-11 | 2014-10-30 | Astrazeneca Ab | Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B |
-
2008
- 2008-10-09 SI SI200831281T patent/SI2201012T1/sl unknown
- 2008-10-09 KR KR1020107010107A patent/KR101494734B1/ko active IP Right Grant
- 2008-10-09 JP JP2010528485A patent/JP4705695B2/ja active Active
- 2008-10-09 WO PCT/GB2008/050925 patent/WO2009047563A1/en active Application Filing
- 2008-10-09 CA CA2701057A patent/CA2701057C/en active Active
- 2008-10-09 AU AU2008309383A patent/AU2008309383B2/en active Active
- 2008-10-09 CN CN200880116651XA patent/CN101861321B/zh active Active
- 2008-10-09 EP EP08806741.8A patent/EP2201012B1/en active Active
- 2008-10-09 RS RS20140457A patent/RS53552B1/en unknown
- 2008-10-09 UY UY31384A patent/UY31384A1/es not_active Application Discontinuation
- 2008-10-09 TW TW097139021A patent/TWI453021B/zh active
- 2008-10-09 DK DK08806741.8T patent/DK2201012T3/da active
- 2008-10-09 PL PL08806741T patent/PL2201012T3/pl unknown
- 2008-10-09 ES ES08806741.8T patent/ES2522365T3/es active Active
- 2008-10-09 ME MEP-2014-102A patent/ME01999B/me unknown
- 2008-10-09 BR BRPI0818533A patent/BRPI0818533B8/pt active IP Right Grant
- 2008-10-09 EA EA201000552A patent/EA018512B1/ru not_active IP Right Cessation
- 2008-10-09 MY MYPI2010001617A patent/MY150059A/en unknown
- 2008-10-09 PT PT88067418T patent/PT2201012E/pt unknown
- 2008-10-09 NZ NZ585261A patent/NZ585261A/en unknown
- 2008-10-09 MX MX2010003927A patent/MX2010003927A/es active IP Right Grant
- 2008-10-10 US US12/249,477 patent/US8101623B2/en active Active
- 2008-10-10 PE PE2012002041A patent/PE20130152A1/es not_active Application Discontinuation
- 2008-10-10 AR ARP080104450A patent/AR068846A1/es active IP Right Grant
- 2008-10-10 PE PE2008001748A patent/PE20090964A1/es active IP Right Grant
- 2008-10-10 CL CL2008003023A patent/CL2008003023A1/es unknown
- 2008-10-11 SA SA8290625A patent/SA08290625B1/ar unknown
-
2010
- 2010-03-25 IL IL204721A patent/IL204721A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02318A patent/ZA201002318B/en unknown
- 2010-04-09 DO DO2010000103A patent/DOP2010000103A/es unknown
- 2010-04-09 GT GT201000082A patent/GT201000082A/es unknown
- 2010-04-09 HN HN2010000653A patent/HN2010000653A/es unknown
- 2010-04-09 CU CU20100062A patent/CU23886B1/es active IP Right Grant
- 2010-04-09 NI NI201000050A patent/NI201000050A/es unknown
- 2010-04-09 CR CR11359A patent/CR11359A/es unknown
- 2010-05-06 CO CO10054272A patent/CO6270328A2/es active IP Right Grant
- 2010-10-12 HK HK10109649.4A patent/HK1143154A1/xx unknown
-
2011
- 2011-03-09 JP JP2011051117A patent/JP5330430B2/ja active Active
- 2011-12-13 US US13/324,191 patent/US20120190679A1/en not_active Abandoned
-
2014
- 2014-08-26 HR HRP20140807AT patent/HRP20140807T1/hr unknown
- 2014-08-28 CY CY20141100689T patent/CY1116929T1/el unknown
-
2015
- 2015-02-19 US US14/626,303 patent/US9492453B2/en active Active
-
2016
- 2016-11-15 US US15/351,481 patent/US10059714B2/en active Active
-
2018
- 2018-07-06 US US16/028,979 patent/US10654855B2/en active Active
-
2020
- 2020-04-07 US US16/841,820 patent/US11236095B2/en active Active
-
2021
- 2021-12-16 US US17/644,654 patent/US11760760B2/en active Active
-
2023
- 2023-08-04 US US18/365,286 patent/US20240109902A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130152A1 (es) | Derivados de heterociclo biciclicos como inhibidores de proteina quinasa b | |
RU2405780C2 (ru) | Химические соединения | |
NZ533310A (en) | Benzimidazoles useful as protein kinase inhibitors | |
CY1118836T1 (el) | Αντι-ιϊκα φωσφονικα αναλογα | |
CR7932A (es) | Pirazolo (1,5-a) (1,3,5) derivados de triazina como ligandos de receptor de cannabinoides | |
ECSP066549A (es) | Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos | |
TNSN08283A1 (en) | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | |
PE20160691A1 (es) | Nuevos derivados de triazolo[4,5-d]pirimidina | |
PE20080948A1 (es) | Derivados de imidazol como moduladores de la senda de hedgehog | |
NO20092715L (no) | 5,6,7,8-tetrahydro-imidazo[1,5-A]pyrazinderivater | |
PE20081850A1 (es) | Derivados ciclizados como inhibidores de la eg-5 | |
EA200801001A1 (ru) | Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине | |
ECSP056116A (es) | Ligandos del receptor cannabinoide y usos de los mismos | |
PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
UY28278A1 (es) | Ligandos del receptor cannabinoide y usos de los mismos | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
ECSP055767A (es) | Compuestos de purina y usos de los mismos | |
EA200701114A1 (ru) | Азоловые производные с антимускариновой активностью | |
PE20100737A1 (es) | Nuevos compuestos | |
EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
MXPA05013282A (es) | Derivados de pirimidina como ligandos del receptor de cannabinoides. | |
NO20055655L (no) | Anvendelse av azetidinkarboksamidderivater i terapi | |
PE20081377A1 (es) | Compuestos de tiazol pirazolopirimidina | |
PE20150902A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociado | |
ATE418548T1 (de) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |